Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept Study of Intravenous Nipocalimab in Active Rheumatoid Arthritis
2021-000510-42Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Nipocalimab intravenous with Placebo intravenous (2 arms). Primary endpoint: Change from baseline in DAS28-CRP. Started Jul 2021; status: active.
02
Drugs
nipocalimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-000510-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000510-42.